UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Diabetes & metabolism, 2020-11, Vol.46 (6), p.423-426

Scheen, A.J.

2020

Volltextzugriff (PDF)

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

Diabetes & metabolism, 2019-06, Vol.45 (3), p.213-223

Scheen, A.J.

2019

Volltextzugriff (PDF)

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Diabetes & metabolism, 2018-12, Vol.44 (6), p.457-464

2018

Volltextzugriff (PDF)

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Diabetes & metabolism, 2012-04, Vol.38 (2), p.89-101

Scheen, A.J

2012

Volltextzugriff (PDF)

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.648-658

Scheen, A.J

2010

Volltextzugriff (PDF)

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes

Diabetes & metabolism, 2019-04, Vol.45 (2), p.110-121

Scheen, A.J.

2019

Volltextzugriff (PDF)

Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials

Diabetes & metabolism, 2020-06, Vol.46 (3), p.186-196

Scheen, A.J.

2020

Volltextzugriff (PDF)

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Diabetes & metabolism, 2020-09, Vol.46 (4), p.265-271

2020

Volltextzugriff (PDF)

Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes

Diabetes & metabolism, 2013-05, Vol.39 (3), p.179-190

2013

Volltextzugriff (PDF)

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?

Diabetes & metabolism, 2020-10, Vol.46 (5), p.343-344

Scheen, A.J.

2020

Volltextzugriff (PDF)

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

Diabetes & metabolism, 2014-06, Vol.40 (3), p.176-185

2014

Volltextzugriff (PDF)

Challenging 2019 ESC guidelines for the management of type 2 diabetes

Diabetes & metabolism, 2020-06, Vol.46 (3), p.181-185

Scheen, A.J.

2020

Volltextzugriff (PDF)

Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies

Diabetes & metabolism, 2018-11, Vol.44 (5), p.386-392

Scheen, A.J.

2018

Volltextzugriff (PDF)

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

Diabetes & metabolism, 2016-09, Vol.42 (4), p.224-233

Scheen, A.J

2016

Volltextzugriff (PDF)

Polyploidy in arctic plants

Biological Journal of the Linnean Society, 2004-08, Vol.82 (4), p.521-536

2004

Volltextzugriff (PDF)

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

Diabetes & metabolism, 2015-06, Vol.41 (3), p.183-194

2015

Volltextzugriff (PDF)

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

Diabetes & metabolism, 2014-12, Vol.40 (6), p.S4-S11

2014

Volltextzugriff (PDF)

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials

Diabetes & metabolism, 2004-12, Vol.30 (6), p.487-496

SCHEEN, A. J

2004

Volltextzugriff (PDF)

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME

Diabetes & metabolism, 2017-04, Vol.43 (2), p.99-109

2017

Volltextzugriff (PDF)

CA-021: Antihyperglycémiants, antihypertenseurs et hypolipidémiants : comparaison des effets sur la mortalité et la morbidité cardiovasculaire chez le patient diabétique de type 2

Diabetes & metabolism, 2016-03, Vol.42, p.A40-A40

Scheen, A

2016

Volltextzugriff (PDF)

CO-30: Les résultats de réduction de mortalité cardiovasculaire et totale avec l'empagliflozine peuvent-ils s'expliquer par un effet diurétique ?

Diabetes & metabolism, 2016-03, Vol.42, p.A9-A9

Scheen, A

2016

Volltextzugriff (PDF)

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes

Diabetes & metabolism, 2017-09, Vol.43 (4), p.299-313

2017

Volltextzugriff (PDF)

Renal outcomes with dipeptidyl peptidase-4 inhibitors

Diabetes & metabolism, 2018-03, Vol.44 (2), p.101-111

2018

Volltextzugriff (PDF)

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

Diabetes & metabolism, 2004-12, Vol.30 (6), p.498-505

SCHEEN, A. J

2004

Volltextzugriff (PDF)

Cardiovascular Risk-Benefit Profile of Sibutramine

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (5), p.321-334

Scheen, André J.

2010

Volltextzugriff (PDF)

1 – 25 von 2.007

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.634)
Mit Volltextzugriff
(1.020)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.085)
Französisch
(871)
Deutsch
(66)
Japanisch
(60)
Norwegisch
(2)
Russisch
(2)
Spanisch
(2)
Polnisch
(1)

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.154)
Human Health Sciences
(587)
Sciences De La Santé Humaine
(587)
Science & Technology
(547)
Life Sciences & Biomedicine
(517)
Endocrinologie, Métabolisme & Nutrition
(494)
Endocrinology, Metabolism & Nutrition
(494)
Male
(292)
Endocrinology & Metabolism
(278)
Female
(278)
Diabetes Mellitus, Type 2 - Drug Therapy
(265)
Pharmacie, Pharmacologie & Toxicologie
(248)
Pharmacy, Pharmacology & Toxicology
(248)
Adult
(236)
Hypoglycemic Agents - Therapeutic Use
(208)
Biological And Medical Sciences
(184)
Middle Aged
(184)
Risk Factors
(170)
Medical Sciences
(161)
Type 2 Diabetes
(139)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Revue Médicale De Liège
(532)
Revue Médicale Suisse
(134)
Diabetes & Metabolism
(120)
Médecine Des Maladies Métaboliques
(54)
The Lancet
(32)
Diabetes Care
(28)
The Journal Of Clinical Endocrinology And Metabolism
(27)
Diabetologia
(22)
Lancet
(20)
International Journal Of Obesity
(19)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes

Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

Challenging 2019 ESC guidelines for the management of type 2 diabetes

Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

Polyploidy in arctic plants

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME

CA-021: Antihyperglycémiants, antihypertenseurs et hypolipidémiants : comparaison des effets sur la mortalité et la morbidité cardiovasculaire chez le patient diabétique de type 2

CO-30: Les résultats de réduction de mortalité cardiovasculaire et totale avec l'empagliflozine peuvent-ils s'expliquer par un effet diurétique ?

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes

Renal outcomes with dipeptidyl peptidase-4 inhibitors

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

Cardiovascular Risk-Benefit Profile of Sibutramine

Suchergebnisse filtern